Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera

Leukemia

Volumn 21, Issue 9, 2007, Pages 1960-1963

  Pardanani, A ^a   Lasho, T L ^a   Finke, C ^a   Hanson, C A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; RETICULIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DNA DETERMINATION; DNA SEQUENCE; ERYTHROCYTOSIS; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; PERIPHERAL BLOOD STEM CELL; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 34548128326     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404810     Document Type: Article

References (13)

1. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6: 550-566.
2. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. Vinactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM, patients with clonal hematopoiesis. Blood 2006; 107 4139-4141.
3. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-1867.
4. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: 1140-1151.
5. Grunebach F, Bross-Bach U, Kanz L, Brossart P. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 2006; 20: 2210-2211.
6. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683-687.
7. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006, 108: 3472-3476.
8. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
10. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
11. Butcher CM, Hutton JF, Hahn U, To LB, Bardy P, Lewis I et al. Cellular origin and lineage specificity of the JAK2(V617F) allele in polycythemia vera. Blood 2007; 109: 386-387.
12. Lasho TL, Mesa R, Gilliland DG, Tefferi A. Mutation studies in Cd3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005; 130 797-799.
13. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.